{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:54:52Z","timestamp":1791179692032,"version":"4.1.0"},"reference-count":92,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2026.2204","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:09:24Z","timestamp":1790147364000},"page":"1-15","source":"Crossref","is-referenced-by-count":0,"title":["Fosmanogepix: A comprehensive review of its origin, mechanism, antifungal efficacy, and resistance (Review)"],"prefix":"10.3892","volume":"25","author":[{"given":"Guoxing","family":"Zhu","sequence":"first","affiliation":[{"name":"School of Pharmacy, Taizhou University, Taizhou, Jiangsu 225300, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanyi","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhai","sequence":"additional","affiliation":[{"name":"College of Marine and Biological Engineering, Yancheng Teachers University, Yancheng, Jiangsu 224000\u200c, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Mou","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Taizhou University, Taizhou, Jiangsu 225300, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"key20261005082829_b1-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"e939088","key":"key20261005082829_b2-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.939088","article-title":"Editorial: the World Health Organization (WHO) fungal priority pathogens list in response to emerging fungal pathogens during the COVID-19 pandemic","volume":"28","author":"Parums","year":"2022","journal-title":"Med Sci Monit"},{"issue":"919501","key":"key20261005082829_b3-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.919501","article-title":"COVID-19-associated fungal infections: An urgent need for alternative therapeutic approach?","volume":"13","author":"Doman","year":"2022","journal-title":"Front Microbiol"},{"key":"key20261005082829_b4-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/thorax-2024-222168","article-title":"Climate change: Shifting boundaries of fungal disease in Europe and beyond","volume":"81","author":"Bottery","year":"2025","journal-title":"Thorax"},{"issue":"e171995","key":"key20261005082829_b5-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.3897\/imafungus.17.171995","article-title":"Interconnected worlds: A comprehensive review of fungal defenses, antimicrobial resistance, and their evolutionary dynamics","volume":"17","author":"Sui","year":"2026","journal-title":"IMA Fungus"},{"issue":"874","key":"key20261005082829_b6-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-11235-4","article-title":"Differentiation of Pneumocystis jirovecii pneumonia from colonization: A clinical decision framework incorporating risk stratification and next-generation sequencing thresholds","volume":"25","author":"Sun","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"e0295824","key":"key20261005082829_b7-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02958-24","article-title":"Novel model to predict risk of invasive fungal infection and fungal prophylaxis timing","volume":"13","author":"Zuo","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"565","key":"key20261005082829_b8-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.3390\/jof9050565","article-title":"Fungal drug response and antimicrobial resistance","volume":"9","author":"Osset-Trenor","year":"2023","journal-title":"J Fungi (Basel)"},{"issue":"763","key":"key20261005082829_b9-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00380-8","article-title":"The Lancet Infectious Diseases: An exciting time for antifungal therapy","volume":"23","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"732223","key":"key20261005082829_b10-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.732223","article-title":"Antifungal pipeline","volume":"11","author":"McCarty","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"key20261005082829_b11-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00003495-200969030-00010","article-title":"Liposomal amphotericin B: A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections","volume":"69","author":"Moen","year":"2009","journal-title":"Drugs"},{"issue":"140206","key":"key20261005082829_b12-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2019.02.008","article-title":"Fungal lanosterol 14\u03b1-demethylase: A target for next-generation antifungal design","volume":"1868","author":"Monk","year":"2020","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"issue":"105","key":"key20261005082829_b13-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.3390\/jof4030105","article-title":"Fungal resistance to echinocandins and the MDR phenomenon in Candida glabrata","volume":"4","author":"Healey","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"key20261005082829_b14-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cmi.2019.03.028","article-title":"Resistance of Candida to azoles and echinocandins worldwide","volume":"25","author":"Pristov","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"ofad596","key":"key20261005082829_b15-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad596","article-title":"5-flucytosine longitudinal antifungal susceptibility testing of Cryptococcus neoformans: A substudy of the EnACT trial testing oral amphotericin","volume":"10","author":"McHale","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"key20261005082829_b16-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/myc.12265","article-title":"Emerging drugs and vaccines for candidemia","volume":"57","author":"Moriyama","year":"2014","journal-title":"Mycoses"},{"key":"key20261005082829_b17-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1146\/annurev-micro-032521-015858","article-title":"Candida auris genetics and emergence","volume":"77","author":"Chowdhary","year":"2023","journal-title":"Annu Rev Microbiol"},{"key":"key20261005082829_b18-BR-25-5-02204"},{"issue":"1662442","key":"key20261005082829_b19-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1662442","article-title":"New antifungal strategies and drug development against WHO critical priority fungal pathogens","volume":"15","author":"Li","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"key20261005082829_b20-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"key20261005082829_b21-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jgar.2021.04.012","article-title":"Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019)","volume":"26","author":"Pfaller","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"key20261005082829_b22-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1128\/AAC.00366-11","article-title":"Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis","volume":"55","author":"Hata","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"857","key":"key20261005082829_b23-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.3390\/jof8080857","article-title":"Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents","volume":"8","author":"Wiederhold","year":"2022","journal-title":"J Fungi (Basel)"},{"issue":"e0162322","key":"key20261005082829_b24-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01623-22","article-title":"Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers","volume":"67","author":"Hodges","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b25-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1093\/cid\/ciaf185","article-title":"Fosmanogepix for the treatment of invasive mold diseases caused by Aspergillus species and rare molds: A phase 2, open-label study (AEGIS)","volume":"81","author":"Hodges","year":"2025","journal-title":"Clin Infect Dis"},{"key":"key20261005082829_b26-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1046\/j.1365-2958.2003.03481.x","article-title":"Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly","volume":"48","author":"Tsukahara","year":"2003","journal-title":"Mol Microbiol"},{"key":"key20261005082829_b27-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"23639","DOI":"10.1074\/jbc.M301044200","article-title":"GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast","volume":"278","author":"Umemura","year":"2003","journal-title":"J Biol Chem"},{"key":"key20261005082829_b28-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"e0068221","key":"key20261005082829_b29-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00682-21","article-title":"In vitro activity of APX2041, a new Gwt1 inhibitor, and in vivo efficacy of the prodrug APX2104 against Aspergillus fumigatus","volume":"65","author":"Shaheen","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b30-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1021\/id5000212","article-title":"Chemical genomics-based antifungal drug discovery: Targeting glycosylphosphatidylinositol (GPI) precursor biosynthesis","volume":"1","author":"Mann","year":"2015","journal-title":"ACS Infect Dis"},{"issue":"1102","key":"key20261005082829_b31-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.3390\/jof8101102","article-title":"Calcineurin inhibitors synergize with manogepix to kill diverse human fungal pathogens","volume":"8","author":"Liston","year":"2022","journal-title":"J Fungi (Basel)"},{"issue":"e0032426","key":"key20261005082829_b32-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00324-26","article-title":"New perspectives on antimicrobial agents: Fosmanogepix","volume":"70","author":"Lamoth","year":"2026","journal-title":"Antimicrob Agents Chemother"},{"issue":"100166","key":"key20261005082829_b33-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcsw.2025.100166","article-title":"Rho2-dependent cell wall remodeling boosts the fungistatic activity of manogepix against Aspergillus fumigatus","volume":"15","author":"Brazil","year":"2025","journal-title":"Cell Surf"},{"key":"key20261005082829_b34-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41579-024-01035-z","article-title":"The wound microbiota: Microbial mechanisms of impaired wound healing and infection","volume":"22","author":"Uberoi","year":"2024","journal-title":"Nat Rev Microbiol"},{"issue":"e0013725","key":"key20261005082829_b35-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00137-25","article-title":"Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains","volume":"69","author":"Ceballos-Garzon","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b36-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e01387","DOI":"10.1128\/AAC.01387-19","article-title":"Evaluation of resistance development to the Gwt1 inhibitor manogepix (APX001A) in Candida species","volume":"64","author":"Kapoor","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"9194","key":"key20261005082829_b37-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53512-x","article-title":"Structural insights into the inhibition mechanism of fungal GWT1 by manogepix","volume":"15","author":"Dai","year":"2024","journal-title":"Nat Commun"},{"key":"key20261005082829_b38-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e00261","DOI":"10.1128\/AAC.00261-20","article-title":"Enhanced efflux pump expression in Candida mutants results in decreased manogepix susceptibility","volume":"64","author":"Liston","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"e0150824","key":"key20261005082829_b39-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01508-24","article-title":"TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression","volume":"69","author":"Hirayama","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"e0068025","key":"key20261005082829_b40-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00680-25","article-title":"Mutations in transcription factors that confer fluconazole resistance also confer reduced susceptibility to manogepix in Candida auris (Candidozyma auris), Candida albicans, Candida parapsilosis, and Candida glabrata (Nakaseomyces glabratus)","volume":"69","author":"Barker","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b41-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.chom.2019.08.004","article-title":"Calcium-calmodulin-calcineurin signaling: A globally conserved virulence cascade in eukaryotic microbial pathogens","volume":"26","author":"Park","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"2573","key":"key20261005082829_b42-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02573","article-title":"Fungal cell wall: Emerging antifungals and drug resistance","volume":"10","author":"Lima","year":"2019","journal-title":"Front Microbiol"},{"issue":"e0254625","key":"key20261005082829_b43-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02546-25","article-title":"Echinocandin tolerance and persistence in vitro are regulated by calcineurin signaling in Candida glabrata","volume":"17","author":"Harrington","year":"2026","journal-title":"mBio"},{"issue":"e59210","key":"key20261005082829_b44-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59210","article-title":"Fosmanogepix: the novel anti-fungal agent's comprehensive review of in vitro, in vivo, and current insights from advancing clinical trials","volume":"16","author":"Almajid","year":"2024","journal-title":"Cureus"},{"key":"key20261005082829_b45-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e00429","DOI":"10.1128\/AAC.00429-20","article-title":"Manogepix (APX001A) displays potent in vitro activity against human pathogenic yeast, but with an unexpected correlation to fluconazole MICs","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b46-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e01225","DOI":"10.1128\/AAC.01225-18","article-title":"APX001A in vitro activity against contemporary blood isolates and Candida auris determined by the EUCAST reference method","volume":"62","author":"Arendrup","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b47-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.diagmicrobio.2011.05.001","article-title":"In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method","volume":"71","author":"Pfaller","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key20261005082829_b48-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e00840","DOI":"10.1128\/AAC.00840-19","article-title":"In vitro activity of APX001A (Manogepix) and comparator agents against 1,706 fungal Isolates collected during an international surveillance program in 2017","volume":"63","author":"Pfaller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b49-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1128\/AAC.03944-14","article-title":"The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans","volume":"59","author":"Wiederhold","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b50-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b51-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1093\/jac\/dkr342","article-title":"Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: Comparison of CLSI and European committee on antimicrobial susceptibility testing methods","volume":"66","author":"Pfaller","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"e0113223","key":"key20261005082829_b52-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01132-23","article-title":"In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022)","volume":"68","author":"Pfaller","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b53-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.cmi.2024.03.006","article-title":"New treatment options for critically important WHO fungal priority pathogens","volume":"31","author":"Kriegl","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"key20261005082829_b54-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e00523","DOI":"10.1128\/AAC.00523-18","article-title":"In vitro and in vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against Cryptococcus","volume":"62","author":"Shaw","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"ofac492.1665","key":"key20261005082829_b55-BR-25-5-02204","article-title":"2043. In vitro activity of manogepix against 2,810 fungal isolates from the SENTRY surveillance program (2020-2021) stratified by infection type","volume":"15 (Supp 2)","author":"Huband","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"key20261005082829_b56-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/jac\/dkz022","article-title":"In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies","volume":"74","author":"Rivero-Menendez","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"e0171721","key":"key20261005082829_b57-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01717-21","article-title":"In vitro antifungal activity of manogepix and other antifungal agents against South African Candida auris isolates from bloodstream infections","volume":"10","author":"Maphanga","year":"2022","journal-title":"Microbiol Spectr"},{"key":"key20261005082829_b58-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1128\/AAC.05414-11","article-title":"Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods","volume":"56","author":"Castanheira","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b59-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e01124","DOI":"10.1128\/AAC.01124-20","article-title":"In vitro activity of manogepix against multidrug-resistant and panresistant Candida auris from the New York outbreak","volume":"64","author":"Zhu","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b60-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e00656","DOI":"10.1128\/AAC.00656-20","article-title":"Manogepix (APX001A) in vitro activity against Candida auris: Head-to-head comparison of EUCAST and CLSI MICs","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"dkag016","key":"key20261005082829_b61-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkag016","article-title":"Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019-24)","volume":"81","author":"Chen","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"key20261005082829_b62-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e00730","DOI":"10.1128\/AAC.00730-20","article-title":"In vitro activity of manogepix (APX001A) and comparators against contemporary molds: MEC comparison and preliminary experience with colorimetric MIC determination","volume":"64","author":"Jorgensen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b63-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3201\/eid3008.240096","article-title":"Environmental hot spots and resistance-associated application practices for azole-resistant Aspergillus fumigatus, Denmark, 2020-2023","volume":"30","author":"Arendrup","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"key20261005082829_b64-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e02343","DOI":"10.1128\/AAC.02343-20","article-title":"Manogepix, the active moiety of the investigational agent fosmanogepix, demonstrates in vitro activity against members of the Fusarium oxysporum and Fusarium solani species complexes","volume":"65","author":"Badali","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b65-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e00178","DOI":"10.1128\/AAC.00178-20","article-title":"Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to Rhizopus arrhizus","volume":"64","author":"Gebremariam","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b66-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e02319","DOI":"10.1128\/AAC.02319-17","article-title":"In vitro and in vivo evaluation of the antifungal activity of APX001A\/APX001 against Candida auris","volume":"62","author":"Hager","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b67-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e01120","DOI":"10.1128\/AAC.01120-19","article-title":"Efficacy of delayed therapy with fosmanogepix (APX001) in a murine model of Candida auris invasive candidiasis","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b68-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e01713","DOI":"10.1128\/AAC.01713-18","article-title":"APX001 is effective in the treatment of murine invasive pulmonary aspergillosis","volume":"63","author":"Gebremariam","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b69-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e01715","DOI":"10.1128\/AAC.01715-18","article-title":"APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccidioides immitis pneumonia","volume":"63","author":"Viriyakosol","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b70-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e01735","DOI":"10.1128\/AAC.01735-19","article-title":"Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis","volume":"64","author":"Alkhazraji","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"e0038022","key":"key20261005082829_b71-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00380-22","article-title":"The combination treatment of fosmanogepix and liposomal amphotericin B is superior to monotherapy in treating experimental invasive mold infections","volume":"66","author":"Gebremariam","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"S526","key":"key20261005082829_b72-BR-25-5-02204","article-title":"First-in-human study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects","volume":"4 (suppl 1)","author":"Hodges","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"S534","key":"key20261005082829_b73-BR-25-5-02204","article-title":"Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability","volume":"4 (suppl 1)","author":"Hodges","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"key20261005082829_b74-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1093\/jac\/dkad269","article-title":"Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia","volume":"78","author":"Cornely","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"e0141922","key":"key20261005082829_b75-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01419-22","article-title":"Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by Candida auris: Results from a phase 2 trial","volume":"67","author":"Vazquez","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b76-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1093\/jac\/dkad256","article-title":"Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: Results from a phase 2 trial","volume":"78","author":"Pappas","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"ciag271","key":"key20261005082829_b77-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag271","article-title":"Fosmanogepix treatment for coccidioidomycosis under an expanded access program","volume":"21","author":"Cohen","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"5352","key":"key20261005082829_b78-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32249-5","article-title":"The importance of antimicrobial resistance in medical mycology","volume":"13","author":"Gow","year":"2022","journal-title":"Nat Commun"},{"issue":"e0164522","key":"key20261005082829_b79-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01645-22","article-title":"Heightened efficacy of anidulafungin when used in combination with manogepix or 5-flucytosine against Candida auris in vitro","volume":"67","author":"John","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"myad118","key":"key20261005082829_b80-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myad118","article-title":"The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo","volume":"61","author":"Konings","year":"2023","journal-title":"Med Mycol"},{"key":"key20261005082829_b81-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12281-023-00463-3","article-title":"Novel approaches in the management of mucormycosis","volume":"8","author":"Lamoth","year":"2023","journal-title":"Curr Fungal Infect Rep"},{"key":"key20261005082829_b82-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e01795","DOI":"10.1128\/AAC.01795-20","article-title":"Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of Candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits","volume":"65","author":"Petraitiene","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"91","key":"key20261005082829_b83-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.3390\/idr17040091","article-title":"Antifungal agents in the 21st century: advances, challenges, and future perspectives","volume":"17","author":"Branda","year":"2025","journal-title":"Infect Dis Rep"},{"issue":"e12960","key":"key20261005082829_b84-BR-25-5-02204","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12960","article-title":"Antifungal chemotherapies and immunotherapies for the future","volume":"45","author":"Armstrong-James","year":"2023","journal-title":"Parasite Immunol"},{"key":"key20261005082829_b85-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1584\/jpestics.D20-094","article-title":"Aminopyrifen, a novel 2-aminonicotinate fungicide with a unique effect and broad-spectrum activity against plant pathogenic fungi","volume":"46","author":"Hatamoto","year":"2021","journal-title":"J Pestic Sci"},{"key":"key20261005082829_b86-BR-25-5-02204","first-page":"24","article-title":"Understanding inflammatory bowel disease: an integrative framework of microbiome, metabolome, and immunological biomarkers","volume":"3","author":"Prabhu","year":"2025","journal-title":"J Transl Gastroenterol"},{"key":"key20261005082829_b87-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1093\/jac\/dky302","article-title":"Activity of novel antifungal compound APX001A against a large collection of Candida auris","volume":"73","author":"Berkow","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key20261005082829_b88-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1128\/AAC.00570-11","article-title":"In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods","volume":"55","author":"Pfaller","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b89-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e02542","DOI":"10.1128\/AAC.02542-17","article-title":"In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated Candidiasis mouse model","volume":"62","author":"Zhao","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b90-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e00425","DOI":"10.1128\/AAC.00425-18","article-title":"Significantly improved pharmacokinetics enhances in vivo efficacy of APX001 against echinocandin- and multidrug resistant Candida isolates in a mouse model of invasive Candidiasis","volume":"62","author":"Zhao","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b91-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e02372","DOI":"10.1128\/AAC.02372-18","article-title":"APX001 pharmacokinetic\/pharmacodynamic target determination against Aspergillus fumigatus in an in vivo model of invasive pulmonary Aspergillosis","volume":"63","author":"Zhao","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"key20261005082829_b92-BR-25-5-02204","doi-asserted-by":"publisher","first-page":"e01966","DOI":"10.1128\/AAC.01966-19","article-title":"Galactomannan is a biomarker of Fosmanogepix (APX001) efficacy in treating experimental invasive pulmonary Aspergillosis","volume":"64","author":"Gebremariam","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:28:33Z","timestamp":1791178113000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2026.2204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":92,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,23]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2026.2204","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}